Samsung is moving into the biotechnology business

Lee Jae-yongBloomberg FinanceSamsung vice chairman Lee Jae-yong.

Samsung hosted an event to celebrate the announcement of a new biotechnology manufacturing plant, The Wall Street Journal reports.

The event was attended by Samsung employees and the future chairman Lee Jae-yong, son of Lee Kun-hee, who is the current chairman.

According to the WSJ, Samsung is looking to manufacture more biologic drugs, which are made from living cells and blood components rather than chemicals. This technology can be used to treat cancer and arthritis, among other things.

Samsung is applying its knowledge from making computer chips and other manufacturing to the new biotechnology plant. The company is looking to become the largest contract maker of biologic drugs, according to the WSJ, by making the process of manufacturing the drugs smoother and more efficient.

“Our new plant has been designed to allow operations to continue throughout the year, almost nonstop,” said Samsung BioLogics chief-executive Kim Tae-han.

NOW WATCH: I visited Amazon’s first retail store, and one thing was especially annoying

NOW WATCH: Tech Insider videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at

Tagged In

sai-us samsung science uk